E Fund Management Co. Ltd. Acquires 1,069 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

E Fund Management Co. Ltd. lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 47.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 3,340 shares of the biopharmaceutical company’s stock after purchasing an additional 1,069 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $639,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Harbor Capital Advisors Inc. boosted its holdings in Alnylam Pharmaceuticals by 1.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock valued at $562,000 after purchasing an additional 51 shares in the last quarter. EP Wealth Advisors LLC raised its stake in Alnylam Pharmaceuticals by 6.4% during the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 71 shares in the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 2.1% during the third quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company’s stock valued at $800,000 after acquiring an additional 93 shares during the period. Metis Global Partners LLC boosted its stake in shares of Alnylam Pharmaceuticals by 2.2% in the 4th quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock valued at $839,000 after purchasing an additional 94 shares in the last quarter. Finally, Lindbrook Capital LLC boosted its stake in shares of Alnylam Pharmaceuticals by 37.2% in the 4th quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 100 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock traded down $2.04 during trading hours on Wednesday, reaching $152.29. 451,069 shares of the company’s stock traded hands, compared to its average volume of 750,047. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $218.88. The firm’s 50 day moving average is $149.35 and its 200-day moving average is $164.93. The firm has a market capitalization of $19.26 billion, a price-to-earnings ratio of -56.82 and a beta of 0.41.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same quarter in the prior year, the company earned ($1.40) earnings per share. The company’s quarterly revenue was up 54.8% on a year-over-year basis. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.43 EPS for the current year.

Analysts Set New Price Targets

ALNY has been the subject of several analyst reports. Wells Fargo & Company cut their price target on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a report on Friday, February 16th. HC Wainwright boosted their target price on Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the stock a “buy” rating in a report on Tuesday. BMO Capital Markets restated an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 27th. Wolfe Research began coverage on Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. Finally, Chardan Capital restated a “buy” rating and set a $225.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, May 3rd. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $216.19.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.